mTOR-dependent mitochondrial translocation of TFEB suggests that the efficacy of mTOR inhibitors used in the clinic as immunosuppressant and in cancer therapy is possibly dependent on the mitochondrial activity of TFEB. This evidence concerns the gene TFEB and cancer.